Welcome to our dedicated page for Impact Biomedical SEC filings (Ticker: IBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the right data in Impact BioMedical’s multifaceted biotech disclosures can be daunting. Patents covering the Linebacker™ small-molecule platform, natural 3F™ insect repellents, and the Celios® air-purification technology sit next to intricate R&D expense notes and collaboration revenue tables. For many analysts, searching “Impact BioMedical SEC filings explained simply” still returns dense PDFs, and investors tracking pipeline milestones end up combing through hundreds of pages.
Our SEC filings hub eliminates that friction. AI-powered summaries flag critical passages in every Impact BioMedical annual report 10-K simplified, while side-by-side views of each Impact BioMedical quarterly earnings report 10-Q filing reveal trial spending trends. Receive real-time alerts for Impact BioMedical Form 4 insider transactions—so you know when executives act. Need context on a sudden press release? The platform links every Impact BioMedical 8-K material events explained in plain language. Even the Impact BioMedical proxy statement executive compensation sections are broken down so you can assess incentive alignment without scrolling. It’s understanding Impact BioMedical SEC documents with AI, in seconds.
Because the company’s cash flow depends on licensing, joint ventures, and milestone payments, our analysis highlights deferred revenue disclosures and partner royalty schedules often buried in footnotes. Interactive tools surface Impact BioMedical insider trading Form 4 transactions by officer or drill into “Impact BioMedical executive stock transactions Form 4” to spot buying patterns. Whether you type “Impact BioMedical earnings report filing analysis” or simply want comprehensive coverage of every filing type, Stock Titan’s platform delivers clear answers, AI-generated insights, and continuous updates straight from EDGAR.
Impact Biomedical Inc. proxy content lists company leadership, director cash compensation and limited executive compensation details. The document shows Frank D. Heuszel as Chief Executive Officer and Executive Chairman and includes other officers and directors: Mark Suseck (Chief Operating Officer), Todd D. Macko (Chief Financial Officer), Elise Brownell, Melissa Sims, Chris(tian) Zimmerman, David Keene, Castel Hibbert, Chang Heng Fai Ambrose and Jason Grady. Director cash retainers appear as $1,250 and meeting fees $925, totaling $2,175 for several directors. Reported 2024 compensation items include $126,689 and $32,000 for Mark Suseck (total $158,689) and $555 for Todd D. Macko in 2024. An aggregate ownership line lists 95,779 shares for all officers and directors as a group and notes holdings as <1% for certain entries.
Impact BioMedical, Inc. (IBO) filed a DEF 14C Definitive Information Statement that notifies shareholders of certain corporate actions and discloses ownership and director/officer compensation. The filing states the corporate action(s) will become effective no sooner than 20 days after mailing the Definitive Information Statement as required under Nevada law. Significant disclosed ownership includes DSS, Inc. holding 545,024 shares (4.5%) and the group of all officers and directors holding 95,779 shares (<1%). Reported compensation items include Mark Suseck $158,689 (2024), Todd D. Macko $555 (2024), and multiple directors each receiving $2,175 for the period shown. The document is signed by CEO Frank D. Heuszel in Houston on September 8, 2025. The filing appears focused on notice, ownership, and compensation disclosures rather than earnings or transactions.
Impact BioMedical filed a Preliminary Information Statement regarding corporate actions that will become effective no sooner than 20 days after mailing a Definitive Information Statement to stockholders. The filing discloses beneficial ownership snapshots showing DSS, Inc. holds 545,024 shares (4.5%) and that most named insiders and directors hold less than 1% individually. Director fees are listed at $1,250 cash plus $925 in other compensation for several directors, totaling $2,175 each. Executive pay detail shows Mark Suseck with total 2024 compensation of $158,689 and Todd D. Macko with $555 in 2024. The document includes signatures and appears to be a standard preliminary disclosure under the Exchange Act and Nevada Revised Statutes.
Impact BioMedical, Inc. reported a six-month net loss of $15,631,000 for the period ended June 30, 2025, versus a loss of $1,880,000 a year earlier, driven primarily by a $12,942,000 fair-value adjustment on a related-party note payable. Operating loss for the six months was $2,165,000 while total revenue was nominal at $7,000, reflecting limited commercial sales activity.
At June 30, 2025, total assets were $19.06 million (including $17.565 million of net intangible assets for developed technologies), cash was $624,000, and the related-party note payable was recorded at $22.352 million. Stockholders' deficit was $10.341 million and accumulated deficit increased to $53.283 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it raised $3.726 million in its September 16, 2024 IPO. The company also completed a February 25, 2025 acquisition of DSS PureAir assets for $1.15 million paid in stock, adding inventory and Celios IP.
Impact BioMedical (NYSE:IBO) disclosed in an 8-K that it signed a Merger and Share Exchange Agreement on 21 June 2025 with Dr Ashleys Cayman, newly formed PubCo Dr Ashleys Limited and related entities.
Transaction structure: (i) Merger Sub will merge into Impact, making Impact a wholly-owned subsidiary of PubCo; (ii) immediately after, PubCo will acquire 100% of Dr Ashleys Cayman. Post-closing ownership will be 94.20 % Dr Ashleys Cayman shareholder, 4.80 % Impact shareholders and 1.00 % BMI Capital. A reverse stock split of Impact shares will occur immediately before closing to facilitate the exchange ratio.
Consideration mechanics: each Impact common share, preferred conversion share, option and warrant (after conversion/cancellation) will be exchanged for PubCo ordinary shares representing the 4.80 % aggregate stake. Impact must have ≥ $10,000 net cash and zero net debt at closing. NYSE American must conditionally approve listing of PubCo shares.
Governance changes: Impact will be renamed "Dr Ashleys USA Inc."; all current Impact directors and officers will resign. New board and officers for both Impact and PubCo will be designated by Dr Ashleys Cayman. Support agreements covering 86.81 % of Impact’s shares commit to vote in favour of the deal.
Key conditions & rights: customary accuracy of reps & warranties, absence of material adverse effect, effectiveness of a registration statement, no blocking injunctions, and termination rights for breach or superior proposals. A Transition Agreement with DSS, Inc. was executed to ensure orderly hand-over of operations.
The filing attaches the Merger Agreement (Exhibit 2.1), Voting Agreement (Exhibit 10.1) and Transition Agreement (Exhibit 10.2) for full terms.
FAQ
What is the current stock price of Impact Biomedical (IBO)?
What is the market cap of Impact Biomedical (IBO)?
